Related Experiment Video
Updated: Nov 19, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
ATP1B3 Restricts Hepatitis B Virus Replication Via Reducing the Expression of the Envelope Proteins
Jun Zhang1, Tianhang Zheng1, Xiaolei Zhou1
1Institute of Virology and AIDS Research, the First Hospital of Jilin University, Changchun, 130021, China.
Abstract:
Our recent study reported that ATP1B3 inhibits hepatitis B virus (HBV) replication via inducing NF-κB activation. However, ATP1B3 mutants which were defective in NF-κB activation still maintained the moderate degree of suppression on HBV replication, suggesting that another uncharacterized mechanism is also responsible for ATP1B3-mediated HBV suppression. Here, we demonstrated that ATP1B3 reduced the expression of HBV envelope proteins LHBs, MHBs and SHBs, but had no effect on intracellular HBV DNA, RNA levels as well as HBV promoter activities. Further investigation showed that proteasome inhibitor MG132 rescued ATP1B3-mediated envelope proteins degradation, demonstrating that proteasome-dependent pathway is involved in ATP1B3-induced degradation of envelope proteins. Co-IP showed that ATP1B3 interacts with LHBs and MHBs and induces LHBs and MHBs polyubiquitination. Immunofluorescence co-localization analysis confirmed LHBs and MHBs colocalized with ATP1B3 together. Our work provides important information for targeting ATP1B3 as a potential therapeutic molecule for HBV infection.
Insights
ATP1B3 protein degrades hepatitis B virus (HBV) envelope proteins via the proteasome pathway, offering a new therapeutic target for HBV infection.
Area of Science:
- Virology
- Molecular Biology
- Biochemistry
Background:
- ATP1B3 was previously shown to inhibit hepatitis B virus (HBV) replication through NF-κB activation.
- Mutant ATP1B3 proteins, despite lacking NF-κB activation, still suppressed HBV replication, indicating an alternative mechanism.
- This study investigates the uncharacterized pathway of ATP1B3-mediated HBV suppression.
Purpose of the Study:
- To elucidate the novel mechanism by which ATP1B3 suppresses HBV replication.
- To investigate the role of ATP1B3 in the degradation of HBV envelope proteins.
- To explore the potential of ATP1B3 as a therapeutic target for HBV infection.
Main Methods:
- Western blotting to assess HBV envelope protein expression.
- Proteasome inhibitor MG132 treatment to evaluate protein degradation pathways.
- Co-immunoprecipitation (Co-IP) assays to detect protein interactions and ubiquitination.
- Immunofluorescence microscopy for co-localization studies.
Main Results:
- ATP1B3 significantly reduced the expression of HBV envelope proteins (LHBs, MHBs, SHBs).
- Proteasome inhibition by MG132 rescued the degradation of envelope proteins, implicating the proteasome pathway.
- ATP1B3 was found to interact with and induce polyubiquitination of LHBs and MHBs.
- Co-localization of ATP1B3 with LHBs and MHBs was confirmed.
Conclusions:
- ATP1B3 suppresses HBV replication by promoting the proteasome-dependent degradation of HBV envelope proteins.
- ATP1B3 interacts with and polyubiquitinates HBV envelope proteins, marking them for degradation.
- Targeting ATP1B3 presents a promising therapeutic strategy for managing HBV infection.
Related Concept Videos
Viruses with RNA Genomes
ATP Synthase: Mechanism
Leaky Scanning

